NDAINTRAVENOUSPOWDER
Approved
Jun 2017
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
6
Data completeness
4/8 — Partial
PANTOPRAZOLE SODIUM (pantoprazole sodium) by Hikma is (h, k)-atpase enzyme system at the secretory surface of the gastric parietal cell. Approved for gastroesophageal reflux disease, gastric ulcer, duodenal ulcer. First approved in 2017.
Drug data last refreshed 20h ago
Mechanism of Action
(H, K)-ATPase enzyme system at the secretory surface of the gastric parietal cell. This effect leads to inhibition of both basal and stimulated gastric acid secretion irrespective of the stimulus. The binding to the (H, K)-ATPase results in a duration of antisecretory effect that persists longer…
Indications (3)
Worked on PANTOPRAZOLE SODIUM at Hikma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.